Jacqueline Shea
Chief Executive Officer presso INOVIO PHARMACEUTICALS, INC.
Patrimonio netto: 284 707 $ in data 31/03/2024
Profilo
Jacqueline E.
Shea is currently the President, Chief Executive Officer & Director at Inovio Pharmaceuticals, Inc. and a Trustee at Albert B.
Sabin Vaccine Institute, Inc. Previously, she served as the Chief Executive Officer at Aeras Global TB Vaccine Foundation from 2015 to 2018.
Prior to that, she was the Vice President-Europe Business Development at Emergent BioSolutions, Inc. from 2013 to 2014 and the Vice President & General Manager at The Oxford-Emergent Tuberculosis Consortium Ltd.
from 2008 to 2013.
Dr. Shea completed her undergraduate degree at the University of Bath and holds a doctorate from The National Institute For Medical Research.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 28/02/2024 | 20 512 ( 0.09% ) | 284 707 $ | 31/03/2024 |
Posizioni attive di Jacqueline Shea
| Società | Posizione | Inizio |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Executive Officer | 10/05/2022 |
Albert B. Sabin Vaccine Institute, Inc.
 Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Director/Board Member | 13/08/2019 |
Precedenti posizioni note di Jacqueline Shea
| Società | Posizione | Fine |
|---|---|---|
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Chief Executive Officer | 01/12/2018 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 01/03/2014 |
| The Oxford-Emergent Tuberculosis Consortium Ltd. | Corporate Officer/Principal | 01/01/2013 |
Formazione di Jacqueline Shea
| University of Bath | Undergraduate Degree |
| The National Institute For Medical Research | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Albert B. Sabin Vaccine Institute, Inc.
Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Commercial Services |
| The Oxford-Emergent Tuberculosis Consortium Ltd. |
- Borsa valori
- Insiders
- Jacqueline Shea
